India, Feb. 13 -- Clinical-stage pharmaceutical company KalVista Pharmaceuticals, Inc. (KALV), Tuesday announced positive results from the phase 3 clinical trial demonstrating statistically and clinically significant efficacy of sebetralstat as oral on-demand therapy for hereditary angioedema or HAE.
The late-stage study was the largest and most representative trial ever conducted in HAE, and included adolescents, patients using long-term prophylaxis, and all attack severities and locations.
The clinical trial met all primary and key secondary endpoints and demonstrated a favorable safety profile. HAE attacks treated with both 300 mg and 600 mg of sebetralstat achieved the primary endpoint of beginning of symptom relief significantly fast...